MetAP-2 inhibitor polymersomes for therapeutic administration
Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.
1. A composition comprising a fumagillol derivative formulation having anti-proliferative activity, wherein said formulation comprises a fumagillol derivative that is covalently linked to a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety, wherein the fumagillol derivative is covalently linked with the hydrophobic moiety of said block copolymer, and wherein the hydrophilic polymer moiety is a poly(ethylene glycol) (PEG) polymer and the hydrophobic polymer moiety of said block copolymer is selected from the group consisting of poly(L-lysine), poly(aspartic acid), polyglycolic acid (PGA), poly(D,L-lactic-co-glycolic acid) (PLGA), poly(valerolactone), poly(hydroxybutyrate), poly(hydroxyvalerate), poly(caprolactone) (PCL), and poly(propylene oxide).
2. The composition of claim 1 , wherein said block copolymer is a diblock copolymer.
3. The composition of claim 1 , wherein said formulation is formulated for oral administration, topical administration, IV administration, peritoneal administration, injection, ocular administration, suppository administration, pulmonary administration or inhalation, and nasal administration.
4. The composition of claim 1 , wherein said anti-proliferative activity is an anti-tumor activity.
5. The composition of claim 1 , wherein said fumagillol derivative comprises a derivative selected from the group consisting of 6-O—(N-chloroacetylcarbamoyl) fumagillol (TNP-470), 6-O-(4-methoxyaniline)acetyl fumagillol; 6-O-(3,4,5-trimethexyaniline)acetyl fumagillol; 6-O-(4-(N,N-dimethylethoxy) aniline)acetyl fumagillol; 6-O-(cyclopropylamino)acetyl fumagillol; 6-O-(cyclobutylamino)acetyl fumagillol; 4-((cyclopropylamino)acetyl)oxy-2-(1,2-epoxy-1,5 20 dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1 cyclohexanol; and 4-((cyclobutylamino)acetyl)oxy-2-(1,2-epoxy-1,5 dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol.
6. A method of treating a condition involving or relying upon MetAP-2 activity for its pathology, the method comprising administering a fumagillol derivative formulation comprising a fumagillol derivative having anti-proliferative activity and is covalently linked to a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety, wherein the hydrophilic polymer moiety is a poly(ethylene glycol) (PEG) polymer and the hydrophobic polymer moiety of said block copolymer is selected from the group consisting of poly(L-lysine), poly(aspartic acid), polyglycolic acid (PGA), poly(D,L-lactic-co-glycolic acid) (PLGA), poly(valerolactone), poly(hydroxybutyrate), poly(hydroxyvalerate), poly(caprolactone) (PCL), and poly(propylene oxide).
7. The method of claim 6 , wherein said condition comprises a tumor activity.
8. The method of claim 6 , wherein the condition is selected from the group consisting of cancer, metastatic tumors, psoriasis, age-related macular degeneration (AMD), thyroid hyperplasia, preeclampsia, rheumatoid arthritis and osteo-arthritis, Alzheimer's disease, obesity, pleural effusion, atherosclerosis, endometriosis, diabetic/other retinopathies, ocular neovascularizations, IL-2 therapy associated edema and other edemas, malaria, SARS, HIV, herpes, lupus, IPF, COPD, asthma, cystic fibrosis, transplant rejection, allergic reaction, multiple sclerosis, bacterial infection, viral infection, conditions involving or characterized by vascular hyperpermeability, inflammation, and spinal injury.
9. A method of making a diblock copolymer composition comprising a fumagillol derivative that has anti-proliferative activity, the method comprising conjugating said fumagillol derivative to a diblock copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety, wherein the hydrophilic polymer moiety is a poly(ethylene glycol) (PEG) polymer and the hydrophobic polymer moiety of said block copolymer is selected from the group consisting of poly(L-lysine), poly(aspartic acid), polyglycolic acid (PGA), poly(D,L-lactic-co-glycolic acid) (PLGA), poly(valerolactone), poly(hydroxybutyrate), poly(hydroxyvalerate), poly(caprolactone) (PCL), and poly(propylene oxide).
10. The method of claim 9 , wherein said fumagillol derivative has anti-angiogenic activity.
11. The method of claim 9 , wherein said fumagillol derivative is selected from the group consisting of 6-O—(N-chloroacetylcarbamoyl) fumagillol (TNP-470), 6-O-(4-methoxyaniline)acetyl fumagillol; 6-O-(3,4,5-trimethexyaniline)acetyl fumagillol; 6-O-(4-(N,N-dimethylethoxy)aniline)acetyl fumagillol; 6-O-(cyclopropylamino)acetyl fumagillol; 6-O-(cyclobutylamino)acetyl fumagillol; 4-((cyclopropylamino)acetyl)oxy-2-(1,2-epoxy-1,5 20 dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1 cyclohexanol; and 4-((cyclobutylamino)acetyl)oxy-2-(1,2-epoxy-1,5 dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol.
12. A diblock copolymer composition comprising a fumagillol derivative, said composition produced by the method of claim 9 .
13. The diblock copolymer composition of claim 12 , wherein said fumagillol derivative has anti-proliferative activity.
14. The diblock copolymer composition of claim 13 , wherein said fumagillol derivative comprises a derivative selected from the group consisting of 6-O—(N-chloroacetylcarbamoyl) fumagillol (TNP-470), 6-O-(4-methoxyaniline)acetyl fumagillol; 6-O-(3,4,5-trimethexyaniline)acetyl fumagillol; 6-O-(4-(N,N-dimethylethoxy)aniline)acetyl fumagillol; 6-O-(cyclopropylamino)acetyl fumagillol; 6-O-(cyclobutylamino)acetyl fumagillol; 4-((cyclopropylamino)acetyl)oxy-2-(1,2-epoxy-1,5 20 dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1 cyclohexanol; and 4-((cyclobutylamino)acetyl)oxy-2-(1,2-epoxy-1,5 dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol.